SG25086G - Cardioselective aryloxyl and arylthio-hydroxypropyl piperazinyl acetanilides which affect calcium - Google Patents

Cardioselective aryloxyl and arylthio-hydroxypropyl piperazinyl acetanilides which affect calcium

Info

Publication number
SG25086G
SG25086G SG598/89A SG1989905988A SG25086G SG 25086 G SG25086 G SG 25086G SG 598/89 A SG598/89 A SG 598/89A SG 1989905988 A SG1989905988 A SG 1989905988A SG 25086 G SG25086 G SG 25086G
Authority
SG
Singapore
Prior art keywords
lower alkyl
independently hydrogen
together form
cardioselective
acetanilides
Prior art date
Application number
SG598/89A
Other languages
English (en)
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of SG25086G publication Critical patent/SG25086G/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Cosmetics (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG598/89A 1983-05-18 1984-05-17 Cardioselective aryloxyl and arylthio-hydroxypropyl piperazinyl acetanilides which affect calcium SG25086G (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/495,904 US4567264A (en) 1983-05-18 1983-05-18 Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry

Publications (1)

Publication Number Publication Date
SG25086G true SG25086G (en) 1989-12-29

Family

ID=23970461

Family Applications (1)

Application Number Title Priority Date Filing Date
SG598/89A SG25086G (en) 1983-05-18 1984-05-17 Cardioselective aryloxyl and arylthio-hydroxypropyl piperazinyl acetanilides which affect calcium

Country Status (26)

Country Link
US (1) US4567264A (fr)
EP (1) EP0126449B1 (fr)
JP (1) JPS59219271A (fr)
KR (1) KR890000020B1 (fr)
AT (1) ATE31533T1 (fr)
AU (1) AU566489B2 (fr)
BR (1) BR1100474A (fr)
CA (1) CA1256874A (fr)
CS (1) CS246080B2 (fr)
DE (1) DE3468215D1 (fr)
DK (1) DK168535B1 (fr)
ES (1) ES8601947A1 (fr)
FI (1) FI78479C (fr)
HK (1) HK91989A (fr)
HU (1) HU192404B (fr)
IE (1) IE57487B1 (fr)
IL (1) IL71863A (fr)
MX (1) MX9203001A (fr)
NO (1) NO163618C (fr)
NZ (1) NZ208188A (fr)
PH (1) PH20016A (fr)
PL (2) PL142760B1 (fr)
PT (1) PT78604B (fr)
RU (2) RU2071471C1 (fr)
SG (1) SG25086G (fr)
ZA (1) ZA843746B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028610A (en) * 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
US5359097A (en) * 1988-12-26 1994-10-25 Kowa Company Ltd. Process for preparation of glycidyl ether
ATE223218T1 (de) * 1989-06-23 2002-09-15 Syntex Llc Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
HU209723B (en) * 1990-10-31 1994-10-28 Richter Gedeon Vegyeszet Process for producing of piperazine derivatives
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH10504324A (ja) * 1995-06-07 1998-04-28 デイド、ケミストリー、システムズ、インコーポレイテッド 薬物の免疫原その他の接合体の製造
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
AU778203B2 (en) 2000-02-18 2004-11-25 Gilead Sciences, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
AU2001239827A1 (en) * 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
CA2657986A1 (fr) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Composes de piperazine substitues
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6451798B2 (en) * 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
AU2001238590A1 (en) 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
WO2002007716A2 (fr) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Methode de traitement d'une angine de poitrine
US6693099B2 (en) * 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
CA2454059A1 (fr) * 2001-07-19 2003-01-30 Cv Therapeutics, Inc. Composes de piperazine substitues et leur utilisation en tant qu'inhibiteurs de l'oxydation d'acides gras
US7001909B2 (en) * 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
EP2266590A3 (fr) 2002-02-22 2011-04-20 Shire LLC Système d'administration de substances actives et méthodes de protection et d'administration de substances actives
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
BR0311161A (pt) * 2002-05-21 2005-03-29 Cv Therapeutics Inc Método de tratamento de diabetes
DE60327765D1 (de) 2002-06-24 2009-07-09 Janssen Pharmaceutica Nv Verfahren zur herstellung von n-(2,6-dimethylphenyl)-2-piperazin-1-ylacetamid
US7056924B2 (en) * 2002-07-18 2006-06-06 Cv Therapeutics, Inc. Substituted heterocyclic compounds
EP1806346B1 (fr) * 2002-12-05 2009-07-22 Cv Therapeutics, Inc. Dérivés de Pipérazine substitués et leur utilisation comme inhibiteurs de l'oxydation d'acids gras
JP2006510670A (ja) * 2002-12-05 2006-03-30 シーブイ・セラピューティクス・インコーポレイテッド 置換ヘテロ環化合物
DE60329323D1 (de) * 2003-01-03 2009-10-29 Cv Therapeutics Inc Substituierte heterozyklische verbindungen
AU2004209522A1 (en) * 2003-01-17 2004-08-19 Gilead Palo Alto, Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
NZ544449A (en) * 2003-06-23 2008-10-31 Cv Therapeutics Inc Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
CA2550257A1 (fr) 2003-12-18 2005-07-07 Cv Therapeutics, Inc. Composes piperazine et piperazine 1-akan-2-ol substitues
WO2006008753A1 (fr) * 2004-07-19 2006-01-26 Unichem Laboratories Limited Forme cristalline et amorphe de ranolazine et son processus de fabrication
US7271169B2 (en) * 2004-09-08 2007-09-18 Cv Therapeutics, Inc. Substituted heterocyclic compounds
JP2008526879A (ja) * 2005-01-06 2008-07-24 シーブイ・セラピューティクス・インコーポレイテッド ラノラジンを含有する徐放性薬学的処方物
WO2008047388A2 (fr) * 2006-10-20 2008-04-24 Ind-Swift Laboratories Limited Procédé amélioré de préparation de ranolazine
CA2678319A1 (fr) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Utilisation de la ranolazine dans le traitement des maladies microvasculaires coronaires
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678272A1 (fr) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Utilisation de la ranolazine pour le traitement de maladies cardiovasculaires
WO2008101012A1 (fr) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Utilisation de la ranolazine pour le traitement de maladies microvasculaires non coronariennes
US7943620B2 (en) * 2007-03-07 2011-05-17 Concert Pharmaceuticals, Inc. Anti-anginal compounds
WO2008116083A1 (fr) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Utilisation de ranolazine contre un taux élevé de peptide natriurétique de type b
WO2008139492A2 (fr) * 2007-05-15 2008-11-20 Natco Pharma Limited Procédé de préparation de base de ranolazine de haute pureté
US20080299195A1 (en) * 2007-05-31 2008-12-04 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
WO2008157240A1 (fr) * 2007-06-13 2008-12-24 Auspex Pharmaceuticals, Inc. Pipérazines substituées
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
WO2009153651A1 (fr) * 2008-06-19 2009-12-23 Medichem, S.A. Procédé de préparation d’un dérivé de pipérazine
WO2010025370A2 (fr) * 2008-08-28 2010-03-04 Dr. Reddy's Laboratories Ltd. Préparation de ranolazine
WO2010023687A2 (fr) * 2008-08-28 2010-03-04 Shodhana Laboratories Limited Préparation de la ranolazine, ses sels et des intermédiaires de ceux-ci
WO2010029436A2 (fr) * 2008-09-09 2010-03-18 Actavis Group Ptc Ehf Nouvelles formes solides de sels de ranolazine
EP2356097A2 (fr) * 2008-10-15 2011-08-17 Actavis Group PTC ehf. Ranolazine très pure ou sel de celle-ci de qualité pharmaceutique acceptable
WO2010097805A1 (fr) 2009-02-24 2010-09-02 Lupin Limited Procédé pour la préparation de ranolazine
US8901128B2 (en) 2009-05-28 2014-12-02 Lupin Limited Pharmaceutical compositions of ranolazine
BR112012006433A2 (pt) 2009-09-25 2016-04-19 Lupin Ltd composição de libertação sustentada de ranolazina
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) * 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
NO3175985T3 (fr) 2011-07-01 2018-04-28
CA2849505A1 (fr) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Bloqueurs des canaux sodiques reduisant la secretion de glucagon
CN103570645A (zh) * 2012-08-01 2014-02-12 上海迪赛诺化学制药有限公司 一种制备n-(2,6-二甲基苯基)-2-(1-哌嗪基)乙酰胺的方法
EP3782992A1 (fr) 2015-03-10 2021-02-24 Unichem Laboratories Limited Nouveau procédé de préparation de ranolazine
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (fr) 2016-06-30 2018-01-04 Interquim, S.A. Comprimés multiples à base de ranolazine

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829441A (en) * 1962-01-29 1974-08-13 Smith Kline French Lab Guanidinoalkylbenzodioxan derivatives
US3360529A (en) * 1962-01-29 1967-12-26 Smith Kline French Lab Guanidinoalkylbenzodioxan derivatives
US3496183A (en) * 1964-11-19 1970-02-17 Egyt Gyogyszervegyeszeti Gyar Beta-guanidino-ethyl-piperazine derivatives
DE1795362A1 (de) * 1968-09-19 1972-01-05 Boehringer Mannheim Gmbh Basische AEther und Verfahren zur Herstellung derselben
DE1795375A1 (de) * 1968-09-21 1972-01-05 Boehringer Mannheim Gmbh Basische AEther und Verfahren zur Herstellung derselben
FR2154493B1 (fr) * 1971-09-13 1975-10-31 Kali Chemie Ag
GB1332008A (en) * 1971-09-28 1973-10-03 Pfizer Ltd Piperazine derivatives their preparation and pharmaceutical compositions containing them
GB1374366A (en) * 1972-07-21 1974-11-20 Science Union & Cie Propanol derivatives and a process for their preparation
GB1425559A (en) * 1972-09-01 1976-02-18 Wyeth John & Brother Ltd Pyridine tetrahydropyridine and piperidine derivatives
GB1411531A (en) * 1972-10-24 1975-10-29 Lafon Labor Amino derivatives of 1,4-benzodioxan
US3953448A (en) * 1972-12-07 1976-04-27 Delmar Chemicals Limited Piperazino-anilido compounds
FR2267104A1 (en) * 1974-04-12 1975-11-07 Ferlux Labo Sa Hypotensive and antiarrhythmic piperazines - 1-(3-phenoxy-2-hydroxy propyl)-4-substd. piperazines
FR2310763A1 (fr) * 1975-05-13 1976-12-10 Buzas Andre Derives 1,4-disubstitues de la piperazine, leur procede de preparation et leurs applications
US4335126A (en) * 1977-03-10 1982-06-15 Degussa Aktiengesellschaft 1-[3-(3,4,5-Trimethoxyphenoxy)-2-hydroxy-propyl]-4-aryl-piperazine-derivatives having pharmaceutical activity
FR2462432A2 (fr) * 1979-08-03 1981-02-13 Delalande Sa Nouveaux derives de la 3,4,5 trimethoxy cinnamoyle piperazine, leur procede de preparation et leur application en therapeutique
FR2387971A1 (fr) * 1977-04-19 1978-11-17 Delalande Sa Nouvelles trimethoxy cinnamoyles piperazines, leur procede de preparation et leur application en therapeutique
FR2456738A2 (fr) * 1978-04-10 1980-12-12 Delalande Sa Nouvelles cinnamoyles piperazines et homopiperazines, leur procede de preparation et leur application en therapeutique
JPS6042795B2 (ja) * 1978-10-23 1985-09-25 日本新薬株式会社 カルバモイルピペラジン誘導体
DE3068678D1 (en) * 1979-08-10 1984-08-30 Sandoz Ag 3-aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them
DE2941597A1 (de) * 1979-10-13 1981-04-23 Basf Ag, 6700 Ludwigshafen Piperidinderivate von 4,5-dialkyl-3-hydroxy-pyrrol-2-carbonsaeureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
US4368199A (en) * 1980-01-21 1983-01-11 Delalande S.A. Novel derivatives of 3,4,5-trimethoxy cinnamoyl piperazine, their salts, the process for preparing the same and their application in therapeutics
DE3005287A1 (de) * 1980-02-13 1981-08-20 Basf Ag, 6700 Ludwigshafen Phenylpiperazinderivate von 1,3,4-oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel
US4302469A (en) * 1980-09-10 1981-11-24 Syntex (U.S.A.) Inc. 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants
US4684651A (en) * 1981-03-17 1987-08-04 Mitsubishi Chemical Industries Limited Alkylenedioxybenzene and acid addition salts thereof useful as hypotensives
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4374837A (en) * 1981-07-31 1983-02-22 Laroche Navarron, S.A. Piperazine derivatives of theobromine
US4353901A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones

Also Published As

Publication number Publication date
PL142760B1 (en) 1987-11-30
FI78479C (fi) 1989-08-10
KR890000020B1 (ko) 1989-03-06
HUT34177A (en) 1985-02-28
ZA843746B (en) 1986-01-29
US4567264A (en) 1986-01-28
EP0126449A1 (fr) 1984-11-28
IE57487B1 (en) 1993-02-10
EP0126449B1 (fr) 1987-12-23
MX9203001A (es) 1992-07-01
HK91989A (en) 1989-11-24
RU2083570C1 (ru) 1997-07-10
JPH0469151B2 (fr) 1992-11-05
BR1100474A (pt) 2000-03-14
DE3468215D1 (en) 1988-02-04
PH20016A (en) 1986-09-01
PL252856A1 (en) 1985-11-19
RU2071471C1 (ru) 1997-01-10
ATE31533T1 (de) 1988-01-15
PT78604A (en) 1984-06-01
NZ208188A (en) 1987-10-30
ES532565A0 (es) 1985-12-01
IL71863A (en) 1987-10-30
PL247722A1 (en) 1985-08-13
JPS59219271A (ja) 1984-12-10
PL143558B1 (en) 1988-02-29
AU2834684A (en) 1984-11-22
NO163618B (no) 1990-03-19
CS246080B2 (en) 1986-10-16
KR850002475A (ko) 1985-05-13
FI841989A0 (fi) 1984-05-17
AU566489B2 (en) 1987-10-22
CA1256874A (fr) 1989-07-04
DK248384D0 (da) 1984-05-17
HU192404B (en) 1987-06-29
FI78479B (fi) 1989-04-28
IE841224L (en) 1984-11-18
NO163618C (no) 1990-06-27
ES8601947A1 (es) 1985-12-01
IL71863A0 (en) 1984-09-30
NO841968L (no) 1984-11-19
DK248384A (da) 1984-11-19
FI841989A (fi) 1984-11-19
DK168535B1 (da) 1994-04-18
PT78604B (en) 1986-07-15

Similar Documents

Publication Publication Date Title
SG25086G (en) Cardioselective aryloxyl and arylthio-hydroxypropyl piperazinyl acetanilides which affect calcium
NO903851D0 (no) Fremgangsmaate for fremstilling av n-substituerte-4-pyrimidinaminer og -pyrimidindiaminer, og deres anvendelse som medikamenter.
FI893632A0 (fi) Foereningar.
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
KR950005817A (ko) 5원환을 갖는 벤조-융합된 헤테로사이클릭 화합물, 이의 제조방법, 약제로서의 이의 용도, 진단제로서의 이의 용도 및 이를 함유하는 약제
NO166126C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater.
ATE64736T1 (de) Therapeutisches mittel.
NO163568C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater.
EP0474580A3 (en) Use of 1-(3-(dimethylamino)propyl)-1-phenylphthalenes for the treatment of cerebrovascular disorders
AU2868689A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
SE8105689L (sv) Terapeutiska medel
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
ATE53385T1 (de) Sulfinyl- und sulfonylsubstituierte 3benzazepine.
NO861868L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-oksatian-derivater.
ATE56967T1 (de) Amidderivate.
EA199700299A1 (ru) Азольные соединения с противогрибковой (антимикозной) активностью, применяемые для лечения людей и в ветеринарии
IL61769A (en) 2-(n-(halosubstitutedphenyl)-n-(thienyl-2-methyl)-amino)-2-imidazolines,their preparation and pharmaceutical compositions containing them
IT1256019B (it) Benzofurano-imidazoli per uso come inibitori di aromatasie 17,20-liasi nella profilassi e trattamento del cancro della mammella e nell'iperplasia prostatica benigna
FI850593L (fi) N-(2,6-disubstituerade aromatiska) -n'-pyridinylureafoereningar.